国立がん研究センター東病院 消化管内科 科長

吉野 孝之 よしの たかゆき 先生

基本情報

診療科・主な得意領域

  • 消化器内科
  • 消化管がん薬物療法の新薬開発
  • クリニカルシーケンスによるがん治療最適化と新規バイオマーカーの探索

資格・学会・役職

  • 国立がん研究センター東病院 消化管内科 科長
  • ASCO(American Society of Clinical Oncology) active member
  • ESMO(European Society for Medical Oncology) active member・大腸癌ガイドライン作成委員・Pan-Asia大腸癌ガイドライン委員長・Pan-Asiaガイドラインプロジェクト国際コーディネーター
  • JCOG(日本臨床腫瘍研究グループ) PRC医学審査委員・JCOG運営委員会委員
  • 日本臨床腫瘍学会 理事・教育企画部会長・国際委員会副委員長・評議員
  • 日本がん分子標的治療学会 理事・評議員
  • 大腸癌研究会 ガイドライン作成委員
  • 一般社団法人 22世紀先端医療情報機構 理事長
  • 日本癌治療学会 代議員
  • 大阪医科大学 非常勤講師
  • 平成28年度国立がん研究センター研究開発費28-A-5「がんゲノム情報を用いた全国レベルでのprecision medicine体制構築に関する研究」 主任研究者
  • 平成28年度AMED「産学連携全国がんゲノムスクリーニング事業SCRUM-Japanで組織した遺伝子スクリーニング基盤を利用した、多施設多職種専門家から構成されたExpert Panelによる全国共通遺伝子解析・診断システムの構築および研修プログラムの開発」 主任研究者
  • 平成28年度AMED「臨床研究・治験推進研究事業(2次公募)」産学連携全国がんゲノムスクリーニング(SCRUM-Japan)患者レジストリを活用したHER2陽性の切除不能・再発大腸がんを対象にした医師主導治験 主任研究者
  • 平成29年度AMED「産学連携全国がんゲノムスクリーニング(SCRUM-Japan)患者レジストリを活用したBRAF遺伝子変異陽性切除不能進行・再発大腸がんを対象にした医師主導治験」 主任研究者
  • 平成30年度AMED「SCRUM-Japanの基盤を活用した血液循環腫瘍DNAスクリーニングに基づくFGFR遺伝子異常を有する難治性の治癒切除不能な進行・再発固形がんに対するTAS-120のバスケット型医師主導治験」 主任研究者
  • 産学連携全国がんゲノムスクリーニング事業SCRUM-Japan GI-SCREEN 主任研究者(2015年2月~)
  • Editorial Board member of Annals of Oncology
  • Associate Editor of Therapeutic Advances in Medical Oncology
  • Editorial Board member of Clinical Colorectal Cancer
  • Editorial Board member of International Journal of Clinical Oncology
  • Reviewer of the Lancet Oncology

所属病院

国立がん研究センター東病院

  • 内科 血液内科 精神科 脳神経外科 呼吸器外科 消化器外科 小児科 整形外科 形成外科 皮膚科 泌尿器科 婦人科 眼科 歯科 麻酔科 乳腺外科 呼吸器内科 緩和ケア内科 腫瘍内科 消化器内科 肝胆膵内科 肝胆膵外科 放射線診断科 放射線治療科 頭頸部外科 病理診断科
  • 千葉県柏市柏の葉6丁目5-1
  • つくばエクスプレス 柏の葉キャンパス 西口 東武バス 国立がん研究センター経由(流山おおたかの森駅東口行き、江戸川台駅東口行き、東大西行きの各線) がん研究センター下車 バス6分 JR常磐線(上野~取手) 柏 西口 東武バス 県民プラザ経由国立がん研究センター行き、または税関研修所経由国立がん研究センター行き がん研究センター下車 バス30分 つくばエクスプレス 柏の葉キャンパス 西口 東武バス 国立がん研究センター経由(流山おおたかの森駅東口行き、江戸川台駅東口行き、東大西行きの各線) がん研究センター下車 バス6分 東武野田線 江戸川台 東口 東武バス 国立がん研究センター経由 柏の葉キャンパス駅西口行き 国立がん研究センター下車 バス10分 JR常磐線(上野~取手) 柏 西口 東武バス 県民プラザ経由国立がん研究センター行き、または税関研修所経由国立がん研究センター行き がん研究センター下車 バス30分
  • 04-7133-1111
公式ウェブサイト
国立がん研究センター東病院

医療記事

来歴等

略歴

1989年 防衛医科大学校 入学
1995年 防衛医科大学校 卒業
1995年 防衛医科大学校病院 研修医(1995年~1997年まで)
1997年 国立がんセンター中央病院 臨床検査部・病理部 研修医(1997年~1999年まで)
1999年 国立がんセンター東病院 内視鏡部消化器内科 研修医(1999年~2001年まで)
2001年 国立がんセンター東病院 内視鏡部消化器内科 非常勤医師(2001年~2002年まで)
2002年 静岡県立静岡がんセンター 消化器内科 副医長(2002年~2007年7月まで)
2005年 Mayo Clinic, college of medicine,Vanderbilt-Ingram Cancer Center Dana-Farber Cancer Institute
2007年 国立がんセンター東病院 内視鏡部消化器内科 医員(2007年8月~2010年3月)
2010年 国立がん研究センター東病院 消化管内科 外来・病棟医長(2010年4月~2014年10月まで)
2013年 国立がん研究センター 先端医療開発センタートランスレーショナルリサーチ分野 併任
2014年 国立がん研究センター東病院 消化管内科 科長
2016年 国立がん研究センター東病院 治験管理室室長 併任(2016年3月~2016年12月)
2017年 国立がん研究センター東病院 臨床研究支援部門研究実施管理部長 併任

論文

Ken Demachi, Hideaki Bando, Hisanaga Nomura, Kohei Shitara, Takayuki Yoshino, Masakazu Yamaguchi. Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: A single institutional study. Jpn J Clin Oncol. 2019 in press
Dung T. Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Elez, Salah-Eddin Al-Batran, Patrick M. Boland, Todd Crocenzi, Chloe E. Atreya, Yi Cui, Tong Dai, Patricia Marinello, Pharm, Luis A. Diaz Jr, Thierry André. A Phase II, Open-Label, Study of Pembrolizumab in Treatment Refractory, Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019 in press
Toshiki Masuishi, Hiroya Taniguchi, Daisuke Kotani, Hideaki Bando, Yoshito Komatsu, Kensei Yamaguchi, Takako Eguchi Nakajima, Taroh Satoh, Tomohiro Nishina, Taito Esaki, Masashi Wakabayashi, Shogo Nomura, Koji Takahashi, Hiromi Ono9, Nami Hirano, Noriko Fujishiro, Nozomu Fuse, Akihiro Sato, Atsushi Ohtsu, Takayuki Yoshino. Rationale and design of the BRAVERY study (EPOC1701): A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. ESMO Open. 2019 in press
Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer. Cancer Chemother Pharmacol. 2019 Sep 23. doi: 10.1007/s00280-019-03957-5. [Epub ahead of print] (First and corresponding author)
Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019 Sep 14. doi: 10.1111/cas.14198. [Epub ahead of print] (Corresponding author)
Kentaro Yamazaki, Shigemi Matsumoto, Chiyo K. Imamura, Chiemi Yamagiwa, Ayaka Shimizu, Takayuki Yoshino. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. Jpn J Clin Oncol. 2019 in press
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, Sara Lonardi, Alfredo Falcone, María Luisa Limón, Alberto Sobrero, Claudia Hastedt, Barbara Peil, Florian Voss, Ingolf Griebsch PhD, Eric Van Cutsem. Health-related quality of life in the Phase III LUME-Colon 1 study: comparison and interpretation of results from EORTC QLQ-C30 analyses. Clin Colorectal Cancer. 2019 in press
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019 Sep 30. doi: 10.1056/NEJMoa1908075. [Epub ahead of print]
Filippo Pietrantonio, Rona Yaeger, Alexa B. Schrock, Giovanni Randon, Sandra Romero-Cordoba, Daniele Rossini, Giovanni Fucà, Jeffrey S. Ross, Daisuke Kotani, Russell Madison, Seung Tae Kim, Lisa Salvatore, Alessandra Raimondi, Filippo Pagani, Beatrice Borelli, Federica Perrone, Maria Di Bartolomeo, Vincent A. Miller, Siraj M. Ali, Jeeyun Lee, Takayuki Yoshino, Filippo de Braud, Alfredo Falcone, Jaclyn F. Hechtman, Chiara Cremolini. Atypical RAS mutations in metastatic colorectal cancer. JCO Precis Oncol. 2019 in press
Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clin Cancer Res. 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-2004. [Epub ahead of print]
Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019 Aug 4. doi: 10.1158/1078-0432.CCR-19-1324. [Epub ahead of print]
Satoshi Fujii, Takayuki Yoshino, Kentaro Yamazaki, Kei Muro, Kensei Yamaguchi, Tomohiro Nishina, Satoshi Yuki, Eiji Shinozaki, Kohei Shitara, Hideaki Bando, Sachiyo Mimaki, Chikako Nakai, Koutatsu Matsushima, Yutaka Suzuki, Kiwamu Akagi, Takeharu Yamanaka, Shogo Nomura, Hiroyasu Esumi, Masaya Sugiyama, Nao Nishida, Masashi Mizokami, Yasuhiro Koh, Yukiko Abe, Atsushi Ohtsu, Katsuya Tsuchihara. Histopathological factors affecting the extraction of high-quality genomic DNA from tissue sections for next-generation sequencing. Biomedical Reports 2019 in press
Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope F, Zaanan A, André T. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies. Ann Oncol. 2019 Jul 3. pii: mdz208. doi: 10.1093/annonc/mdz208. [Epub ahead of print]
Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K, Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. Int J Clin Oncol. 2019 Jul 8. doi: 10.1007/s10147-019-01498-8. [Epub ahead of print]
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019 Jun 15. doi: 10.1007/s10147-019-01485-z. [Epub ahead of print]
Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 versus 6 Months of Oxaliplatin-based Adjuvant Chemotherapy for Colon Cancer: The Randomized Phase 3 ACHIEVE Trial. JAMA Oncology 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print] (First and Corresponding author)
Nakamura Y, Sawada K, Fujii S, Yoshino T. HER2-targeted therapy should be shifted toward an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer. ESMO Open. 2019 Jul 8;4(3):e000530. doi: 10.1136/esmoopen-2019-000530. eCollection 2019 (Corresponding author)
Bando H, Kagawa Y, Kato T, Akagi K, Denda T, Nishina T, Komatsu Y, Oki E, Kudo T, Kumamoto H, Yamanaka T, Yoshino T. A multicenter, prospective study of plasma circulating tumor DNA test for detecting RAS mutation in patients with metastatic colorectal cancer. Br J Cancer 2019 Apr 24. doi: 10.1038/s41416-019-0457-y. [Epub ahead of print] (Corresponding author)
Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer. 2019 Mar 21;19(1):255. doi: 10.1186/s12885-019-5479-6.
Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients with BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-in Results From the Phase III BEACON Study. J Clin Oncol. 2019 Mar 20:JCO1802459. doi: 10.1200/JCO.18.02459. [Epub ahead of print]
Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019 Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.
Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T. Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019 Jan 18. doi: 10.1111/cas.13943. [Epub ahead of print]
Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogression during nivolumab treatment in patients with advanced gastric cancer. Gastric Cancer. 2019 Jan 9. doi: 10.1007/s10120-018-00922-8. [Epub ahead of print]
Yamaguchi K, Komatsu Y, Satoh T, Uetake H, Yoshino T, Nishida T, Yamazaki N, Takikawa H, Morimoto T, Chosa M, Sunaya T, Hamada Y, Muro K, Sugihara K. Large-scale, prospective observational study of regorafenib in Japanese patients with metastatic colorectal cancer in a real-world clinical setting. Oncologist. 2019 Jan 3. pii: theoncologist.2018-0377. doi: 10.1634/theoncologist.2018-0377. [Epub ahead of print]

Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer. 2018 Nov 16. pii: S1533-0028(18)30471-7. doi: 10.1016/j.clcc.2018.11.002. [Epub ahead of print] Review.
Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2018 Nov 22. doi: 10.1093/annonc/mdy502. [Epub ahead of print]
Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018 Nov 22. doi: 10.1093/annonc/mdy498. [Epub ahead of print]
Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: A Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Previously Treated Metastatic Colorectal Cancer Patients. Ann Oncol. 2018 Dec 3. doi: 10.1093/annonc/mdy526. [Epub ahead of print] (Corresponding author)
Mishima S, Yoshino T. MSI Status in Colorectal Cancer. Gan To Kagaku Ryoho. 2018 Nov;45(11):1567-1572. Japanese.
Taniguchi H, Okamoto W, Muro K, Akagi K, Hara H, Nishina T, Kajiwara T, Denda T, Hironaka S, Kudo T, Satoh T, Yamanaka T, Abe Y, Fukushima Y, Yoshino T. Clinical validation of newly developed multiplex kit using Luminex xMAPTM technology for detecting simultaneous RAS and BRAF mutations in colorectal cancer: Results of the RASKET-B study. Neoplasia. 2018 Dec;20(12):1219-1226. doi: 10.1016/j.neo.2018.10.004. Epub 2018 Nov 6.
Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. Ann Oncol. 2018 Oct 18. doi: 10.1093/annonc/mdy461. [Epub ahead of print] (First and Corresponding author)
Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K. Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. ESMO Open. 2018 Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018
Bando H, Okamoto W, Fukui T, Yamanaka T, Akagi K, Yoshino T. Utility of the Quasi-monomorphic Variation Range in Unresectable Metastatic Colorectal Cancer Patients. Cancer Sci. 2018 Aug 24. doi: 10.1111/cas.13774. [Epub ahead of print]
Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A. Relationship between thymidine kinase 1 expression and trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A pooled analysis of two randomized clinical trials. Clin Colorectal Cancer. 2018 Jul 26. pii: S1533-0028(18)30261-5. doi: 10.1016/j.clcc.2018.07.009. [Epub ahead of print] (First and Corresponding author)
Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association. Clinical Practice Guidance for Next Generation Sequencing in Cancer Diagnosis and Treatment Edition 1.0. Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.
Yoshino T, Oki E, Nozawa H, Eguchi-Nakajima T, Taniguchi H, Morita S, Takenaka N, Ozawa D, Shirao K. Rationale and design of the TRUSTY Study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open. 2018 Aug 16;3(5):e000411. doi: 10.1136/esmoopen-2018-000411. eCollection 2018 (First and Corresponding author)
Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer. 2018 Jun 1. doi: 10.1007/s10120-018-0843-9. [Epub ahead of print]
Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Ann Oncol. 2018 Jul 13. doi: 10.1093/annonc/mdy241. [Epub ahead of print]
Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Okamoto W, Fujii S. Prognostic and Predictive Value of HER2 Amplification in Patients with Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 May 19. pii: S1533-0028(18)30101-4. doi: 10.1016/j.clcc.2018.05.006. [Epub ahead of print]
Yamazaki K, Taniguchi H, Yoshino T, Akagi K, Ishida H, Ebi H, Nakatani K, Muro K, Yatabe Y, Yamaguchi K, Tsuchihara K. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. Cancer Sci. 2018 Jun;109(6):2074-2079. doi: 10.1111/cas.13617.
Naito Y, Takahashi H, Shitara K, Okamoto W, Bando H, Kuwata T, Kuboki Y, Matsumoto S, Miki I, Yamanaka T, Watanabe A, Kojima M, Ishii G, Fujii S, Niho S, Ikeda M, Fuse N, Ohno I, Sasaki M, Kohno T, Sato A, Ohtsu A, Ochiai A, Yoshino T, Tsuchihara K. Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study. Jpn J Clin Oncol. 2018 Jun 1;48(6):559-564
Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M. Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018 (Corresponding author)
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.
Shinozaki E, Yoshino T, Tsuchihara K. Reply to comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’’. Br J Cancer. 2018 Mar 22. doi: 10.1038/s41416-018-0040-y. [Epub ahead of print] (Corresponding author)
Grothey A, Yoshino T, Bodoky G, Ciuleanu T, Garcia-Carbonero R, García-Alfonso P, Van Cutsem E, Muro K, Mytelka DS, Li L, Lipkovich O, Hsu Y, Sashegyi A, Ferry D, Nasroulah F, Tabernero J. Association of Baseline Absolute Neutrophil Counts and Survival in Patients with Metastatic Colorectal Cancer Treated with Second-Line Anti-Angiogenic Therapies: Exploratory Analyses of the RAISE Trial and Validation in an Electronic Medical Record Dataset. ESMO Open. 2018 Apr 24;3(3):e000347. doi: 10.1136/esmoopen-2018-000347. eCollection 2018.
Nakamura Y, Yoshino T. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer. Oncologist. Oncologist. 2018 Apr 26. pii: theoncologist.2017-0621. doi: 10.1634/theoncologist.2017-0621. [Epub ahead of print] Review. (Corresponding author)
Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, Andre T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A. The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer? Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy064. [Epub ahead of print]
Yoshino T, Hsu Y, Nasroulah F. Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al. Eur J Cancer. 2018 Feb 9. pii: S0959-8049(18)30084-4. doi: 10.1016/j.ejca.2018.01.070. [Epub ahead of print]
Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clinical Colorectal Cancer 2018 Feb 9. pii: S1533-0028(17)30313-4. doi: 10.1016/j.clcc.2018.01.011. [Epub ahead of print]
Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, Shitara K. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer 2018 Jan 31;18(1):120. doi: 10.1186/s12885-018-4057-7.
Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018 Feb 5. pii: CD-17-1226. doi: 10.1158/2159-8290.CD-17-1226. [Epub ahead of print]
Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Jan 31. pii: S2468-1253(18)30009-8. doi: 10.1016/S2468-1253(18)30009-8. [Epub ahead of print]
Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, Shimodaira H, Sekine S, Tanaka T, Chino A, Tomita N, Nakajima T, Hasegawa H, Hinoi T, Hirasawa A, Miyakura Y, Murakami Y, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Kinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Sugihara K, Watanabe T, Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer. J Anus Rectum Colon 2018; 2(Suppl. I): 1-51
Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene. 2018 Jan 19. doi: 10.1038/s41388-017-0035-9. [Epub ahead of print]
Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738. (First and Corresponding author)

Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, Yoshino T. Integrated safety summary for trifluridine/tipiracil (TAS-102). Anticancer Drugs. 2017 Nov 24. doi: 10.1097/CAD.0000000000000554. [Epub ahead of print]
Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausová J, Muro K, Siegel RW, Konrad RJ, Ouyang H, Melemed SA, Ferry D, Nasroulah F, Van Cutsem E. Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study. Ann Oncol. 2017 Dec 7. doi: 10.1093/annonc/mdx767. [Epub ahead of print]
Tanase T, Hamada C, Yoshino T, Ohtsu A. A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer. Anticancer Res. 2017 Oct;37(10):5851-5855.
E. Van Cutsem, A. Falcone, R. Garcia‐Carbonero, Y. Komatsu, A. Pastorino, M. Peeters, Y. Shimada, K. Yamazaki, T. Yoshino, A. Zaniboni, N. Amellal, A. Kanehisha, Robert Winkler, L. Makris, R. J. Mayer, A. Ohtsu, J. Tabernero. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261. eCollection 2017.
Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.308. [Epub ahead of print] (Co-first and Corresponding author)
Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, Kitano S, Ohtsu A, Takiguchi Y, Yoshino T, Ochiai A. Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017 Jul 29. doi: 10.1007/s00432-017-2482-7. [Epub ahead of print]
Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J. Exposure-Response Relationship of Ramucirumab in Patients with Advanced Second-Line Colorectal Cancer: Exploratory Analysis of the RAISE trial. Cancer Chemother Pharmacol. 2017 Jul 25. doi: 10.1007/s00280-017-3380-z. [Epub ahead of print]
Nakamura Y, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, Yoshino T, Ushijima T. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. Cancer Letters 2017 Aug 28;402:100-109. doi: 10.1016/j.canlet.2017.05.017. Epub 2017 May 31.
Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Shogo Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T. A multicenter phase 1/2 study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE). Lancet Oncol. 2017 Jul 28. pii: S1470-2045(17)30425-4. doi: 10.1016/S1470-2045(17)30425-4. [Epub ahead of print] (Corresponding author)
Arnold D, Fuchs C, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Paz-Ares L, Baron A, Okusaka IT, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017 Sep 7. doi: 10.1093/annonc/mdx514. [Epub ahead of print]
Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2017 Mar 27. doi: 10.1007/s10147-017-1101-6. [Epub ahead of print]
Yoshino T, Obermannová R, Bodoky G, Garcia-Carbonero R, Ciuleanu T, Portnoy DC, Kim TW, Hsu Y, Ferry D, Nasroulah F, Tabernero J. Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase 3 Trial. Eur J Cancer. 2017 Jun;78:61-69. doi: 10.1016/j.ejca.2017.03.007. Epub 2017 Apr 13.
Taniguchi H, Iwasa S, Yamazaki K, Yoshino T, Kiryu C, Naka Y, Liew E, Sakata Y. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer. Cancer Science 2017 May;108(5):1013-1021. doi: 10.1111/cas.13227. Epub 2017 May 11
Yoshino T, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Yamanaka K, Iwasaki K, Soeda J, Hihara M, Yamanaka T, Ochiai A, Muro K. Rationale for and Design of the PARADIGM study: Randomized Phase III Study of mFOLFOX6 plus Bevacizumab or Panitumumab in Chemotherapy-Naïve Patients with RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun;16(2):158-163. doi: 10.1016/j.clcc.2017.01.001. Epub 2017 Jan 24
van Geel RM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema M, Faris JE, Eskens FA, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JH. A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.
Hatogai K, Fujii S, Kojima T, Daiko H, Doi T, Ohtsu A, Ochiai A, Takiguchi Y, Yoshino T. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma. BMC Cancer 2017 DOI 10.1186/s12885-016-3041-3 [Epub ahead of print]
Doi T, Fuse N, Yoshino T, Kojima T, Bando H, Miyamoto H, Kaneko M, Osada M, Ohtsu A. A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Cancer Chemother Pharmacol. 2017 Jan;79(1):89-98. doi: 10.1007/s00280-016-3198-0.
Yoshino T, Hyodo I, Nishina T, Narahara H, Sugimoto N, Yoshisue K, Boku N. Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2017 Jan;79(1):107-116. doi: 10.1007/s00280-016-3212-6. (Corresponding author)

Doi A, Kuboki Y, Shitara K, Fukuoka S, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. Gastrointestinal perforation and fistula formation in five cases with colorectal cancer during treatment with regorafenib. Clin Colorectal Cancer. 2016 Dec 28. pii: S1533-0028(16)30257-2. doi: 10.1016/j.clcc.2016.11.003. [Epub ahead of print]
Nagatani Y, Shitara K, Bando H, Kuboki Y, Okamoto W, Kojima T, Yoshino T, Nishida T, Ohtsu A, Doi T. Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer. 2016 Nov 14;16(1):889
Ushijima T, Yoshino T. The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer. Cancer Res. November 15, 2016 76:6443-6444; doi:10.1158/0008-5472.CAN-16-2867
Kotani D, Kuboki Y and Yoshino T. Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan. Curr Colorectal Cancer Rep. 2016 DOI 10.1007/s11888-016-0336-3 s Review. (Corresponding author)
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J. Subgroup analysis in RAISE: A randomized, double-blind phase 3 study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016 Nov;27(11):2082-2090.
Bando H, Rubinstein L, Harris P, Yoshino T, Doi T, Ohtsu A, Welch J, Takebe N. Analysis of Esophago-Gastric Cancer Patients Enrolled in the National Cancer Institute –Cancer Therapy Evaluation Program -Sponsored Phase 1Trials. Gastric Cancer. 2016 Aug 10. [Epub ahead of print]
Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2016 Sep 14. [Epub ahead of print]
Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2016 Aug 18. pii: S1533-0028(16)30119-0. doi: 10.1016/j.clcc.2016.07.012.
Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A and Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer 2016 July 16:467 doi: 10.1186/s12885-016-2491-y
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Jul 5. pii: mdw235. [Epub ahead of print] Review.
Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma Oncotarget. 2016 Jul 26;7(30):47252-47264. doi: 10.18632/oncotarget.10055.
Yamanaka T, Oki E, Yamazaki K, Yamaguchi K, Muro K, Uetake H, Sato T, Nishina T, Ikeda M, Kato T, Kanazawa A, Kusumoto T, Chao C, Lopatin M, Krishnakumar J, Bailey H, Akagi K, Ochiai A, Ohtsu A, Ohashi Y, Yoshino T. The 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer with Surgery Alone: SUNRISE Study. J Clin Oncol. 2016 Jun 20. pii: JCO670414. [Epub ahead of print] (Corresponding author)
Yoshino T, Uetake H, Fujita N, Furuta T, Katori J, Hara N, Muro K. TAS-102 Safety in Metastatic Colorectal Cancer: Results from the First Post-marketing Surveillance Study. Clin Colorectal Cancer. 2016 May 17. pii: S1533-0028(16)30052-4. doi: 10.1016/j.clcc.2016.04.004. [Epub ahead of print] (Corresponding author)
Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, Yoshino T. A Phase 1 Study of Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Japanese Patients. Cancer Sci. 2016 Mar 17. doi: 10.1111/cas.12932. [Epub ahead of print]
Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F. Large-Scale Prospective Pharmacogenomics Study of Oxaliplatin-Induced Neuropathy in Colon Cancer Patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Ann Oncol. 2016 Feb 18. pii: mdw074. [Epub ahead of print]
Yoshino T, Kojima T, Bando H, Yamazaki T, Naito Y, Mukai H, Fuse N, Goto, K, Ito Yuko, Doi T, Ohtsu A. The Effect of Food on the Pharmacokinetics of TAS-102 and its Efficacy and Safety in Patients with Advanced Solid Tumors. Cancer Sci. 2016 Feb 26. doi: 10.1111/cas.12912. [Epub ahead of print] (Corresponding author)
Osera S, Fujii S, Ikematsu H, Miyamoto H, Oono Y, Yano T, Ochiai A, Yoshino T, Ohtsu A, Kaneko K. Clinicopathological, endoscopic, and molecular characteristics of the "skirt" - a new entity of lesions at the margin of laterally spreading tumors. Endoscopy. 2016 Jan 25. [Epub ahead of print]
Doi T, Shitara K, Kojima T, Yoshino T, Dontabhaktuni A, Rebscher H, Tang S, Cosaert J, Ohtsu A. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Jun;77(6):1253-62. doi: 10.1007/s00280-016-3041-7. Epub 2016 Apr 30.
Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, Yoshino T, Doi T, Takiguchi Y, Ohtsu A. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. J Surg Oncol. 2016 Mar;113(4):390-6. doi: 10.1002/jso.24151. Epub 2016 Jan 12.

Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T. Safety and efficacy of TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer: experience at a single institution. Clinical Colorectal Cancer 2015 Nov 27. pii: S1533-0028(15)00150-4. doi: 10.1016/j.clcc.2015.11.005. [Epub ahead of print]
Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A, Ohtsu A. Comprehensive Analyses Using Next-Generation Sequencing and Immunohistochemistry Enable Precise Treatment in Advanced Gastric Cancer. Ann Oncol. 2015 Oct 21. pii: mdv508. Epub ahead of print
Takahashi H, Kaniwa N, Saito Y, Sai K, Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T, Doi T, Takahashi A, Odaka Y, Okuyama M, Sawada JI, Sakamoto H, Yoshida T. Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. BMC Cancer. 2015 Oct 16;15(1):718.
Van Cutsem E, Yoshino T, Hocke J, Oum'Hamed Z, Studeny M, Tabernero J.E. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-blind, Placebo-controlled Phase III Trial of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment Clinical Colorectal Cancer 2015 Oct 9. pii: S1533-0028(15)00115-2. doi: 10.1016/j.clcc.2015.09.005. Epub ahead of print
Doi T, Yoshino T, Shitara K, Matsubara N, Fuse N, Naito Y, Uenaka K, Nakamura T, Hynes SM, Lin AB. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. Anti-Cancer Drugs. 2015 Aug 18. Epub ahead of print
Doi T, Yoshino T, Fuse N, Boku N, Yamazaki K, Koizumi W, Shimada K, Takinishi Y, Ohtsu A. Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. Invest New Drugs. 2015 Jul 12. Epub ahead of print.
Nishina T, Kato T, Yamazaki K, Yoshino T, Miyata Y, Esaki T, Moriwaki T, Boku N, Hyodo I. Phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015 Jul 22. Epub ahead of print
Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Jul 13. pii: S1470-2045(15)00138-2. doi: 10.1016/S1470-2045(15)00138-2. Epub ahead of print.
Yoshino T, Yamazaki K, Gotoh M, Nasroulah F, Gao L, Yoshizuka N, Ohtsu A. Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. Anticancer Res. 2015 Jul;35(7):4003-7.  (Corresponding author)
Hecht JR, Mitchell EP, Yoshino T, Welslau M, Lin X, Chow Maneval E, Paolini J, Lechuga MJ, Kretzschmar A. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Manag Res. 2015 Jun 15;7:165-73. doi: 10.2147/CMAR.S61408. eCollection 2015.
Doi T, Tamura K, Tanabe Y, Yonemori K, Yoshino T, Fuse N, Kodaira M, Bando H, Noguchi K, Shimamoto T, Ohtsu A. Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.Cancer Chemother Pharmacol. 2015 Jun 24. [Epub ahead of print]
Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Cancer Chemother Pharmacol. 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16. (Corresponding author)
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.
Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z. (Corresponding author)
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.
Yoshida M, Muro K, Tsuji A, Hamamoto Y, Yoshino T, Yoshida K, Shirao K, Miyata Y, Takahari D, Takahashi T, Ohtsu A. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer. 2015 May;51(8):935-41. doi: 10.1016/j.ejca.2015.03.007. Epub 2015 Mar 30.
Yoshino T, Muro K, Yamaguchi K, Nishina T, Denda T, Kudo T, Okamoto W, Taniguchi H, Akagi K, Kajiwara T, Hironaka S, Satoh T.Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. EBioMedicine. 2015 Feb 14;2(4):317-23. doi: 10.1016/j.ebiom.2015.02.007. eCollection 2015 Apr. (Corresponding author)
Hashimoto Y, Yoshino T. Chemotherapeutic agents and electrolyte imbalance]. Nihon Rinsho. 2015 Feb;73 Suppl 2:426-31. (Corresponding author)
Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K; Japanese Society of Medical Oncology. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. Cancer Sci. 2015 Mar;106(3):324-7. doi: 10.1111/cas.12595.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015 Apr;20(2):207-39. doi: 10.1007/s10147-015-0801-z. Epub 2015 Mar 18.
Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yoshino T, Ohtsu A, Doi T. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Invest New Drugs. 2015 Jun;33(3):664-70. doi: 10.1007/s10637-015-0231-9. Epub 2015 Mar 15.
Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2015 Feb 15. [Epub ahead of print]
Kotani D, Fukuoka S, Yoshino T. Efficacy of TAS-102. Gan To Kagaku Ryoho. 2015 Jan;42(1):1-5. Review. Japanese. (Corresponding author)
Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, Yoshino T, Asano H, Ochiai A, Komatsu Y, Sakamoto N, Ohtsu A. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. Jpn J Clin Oncol. 2015 Jan;45(1):43-8. doi: 10.1093/jjco/hyu174. Epub 2014 Nov 6.
Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs. 2015 Jun;33(3):740-50. doi: 10.1007/s10637-014-0154-x. Epub 2014 Sep 12. (Corresponding author)
Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

Yoshino T, Yamazaki K, Yamaguchi K, Doi T, Boku N, Machida N, Onozawa Y, Asayama M, Fujino T, Ohtsu A. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2013;31(4):910-7. (Corresponding author)
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.
Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC cancer. 2013;13(1):405. (Corresponding author)
Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current colorectal cancer reports. 2013;9:261-9.
Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13(10):993-1001. (Corresponding author)
Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer. 2012;107:340-4.
Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y, Fukutomi A, Hironaka S, Koizumi W, Sasaki T. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107(3):429-34.
Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. Jpn J Clin Oncol. 2012;42(12):1146-51. (Corresponding author)
Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer. 2011;105(3):403-6. (Corresponding author)

その他

  • 【受賞】Jpn J Clin Oncol Paper of the Year 2013

  • 【受賞】Contribution to the Scholar Journals

本ページにおける情報は、医師本人の申告に基づいて掲載しております。内容については弊社においても可能な限り配慮しておりますが、最新の情報については公開情報等をご確認いただき、またご自身でお問い合わせいただきますようお願いします。

なお、弊社はいかなる場合にも、掲載された情報の誤り、不正確等にもとづく損害に対して責任を負わないものとします。